Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 50Leukemia, Myeloid, Chronic-Phase 32Leukemia 28Leukemia, Myeloid, Acute 18Breast Neoplasms 18Recurrence 15Prostatic Neoplasms 14Leukemia, Lymphocytic, Chronic, B-Cell 13Neoplasm Metastasis 12Blast Crisis 12Multiple Myeloma 11Carcinoma, Non-Small-Cell Lung 11Burkitt Lymphoma 11Pancreatic Neoplasms 10Neoplasms 9Leukemia, Myeloid, Accelerated Phase 9Lung Neoplasms 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 7Glioblastoma 7Melanoma 6Lymphoma 6Glioma 6Rectal Neoplasms 5Philadelphia Chromosome 5Ovarian Neoplasms 5Myelodysplastic Syndromes 5Lymphoma, Large B-Cell, Diffuse 5Hematologic Neoplasms 5

Interventions

Vincristine 3Radiotherapy 3Radiation 3Dactinomycin 3Cyclophosphamide 3Vinorelbine 2Magnetic Resonance Spectroscopy 2Biopsy 2temsirolimus 1ganitumab 1efineptakin alfa 1dinutuximab 1X-Rays 1Specimen Handling 1Sirolimus 1Receptor Protein-Tyrosine Kinases 1Phantoms, Imaging 1Irinotecan 1Imatinib Mesylate 1Dasatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rhabdomyosarcoma, Embryonal × Dasatinib × Clear all
NCT03041701 2022-04-14

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
14 enrolled 17 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡